Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Aug 15, 2023; 15(8): 1451-1460
Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1451
Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1451
Table 2 Anthropometric, biochemical, and histological differences between patients with diagnosed chronic atrophic autoimmune gastritis who developed gastric neuroendocrine tumors and patients with atrophic autoimmune gastritis who did not develop gastric neuroendocrine tumors, n (%)
| AIG patients without gNENs | AIG patients with gNENs | P value | |
| Sex (%) | 84.3 (female) | 78 (female) | 0.06 |
| Age (median) | 61 yr (IQR: 50–69) | 66 yr (IQR: 55–73) | 0.68 |
| Autoimmune tyroiditis | 48 (42) | 13 (39) | 0.46 |
| Type 2 diabetes mellitus | 33 (29) | 11 (33) | 0.33 |
| Psoriasis and/or vitiligo | 6 (5) | 3 (9) | 0.12 |
| Auntoimmune polyglandular syndrome | 5 (4) | 2 (6) | 0.23 |
| APCA positivity | 78 (89.7) | 25 (75.8) | 1.00 |
| ECL simple/linear hyperplasia | 29 (33.3) | 7 (21) | 1.01 |
| ECL micronodular hyperplasia | 23 (26.4) | 11(33.3) | 0.73 |
| ECL macronodular hyperplasia | 6 (6.8) | 1 (3) | 0.94 |
| OLGIM II–IV | 34 (39.1) | 17 (51.5) | 0.49 |
| Chromogranin A (median) | 172 ng/mL (IQR: 107–320) | 160 ng/mL (IQR: 115–217) | 0.68 |
| Gastrin (median) | 688 pg/mL (IQR: 423–1200) | 992 pg/mL (IQR: 449–1500) | 0.03 |
- Citation: Massironi S, Gallo C, Elvevi A, Stegagnini M, Coltro LA, Invernizzi P. Incidence and prevalence of gastric neuroendocrine tumors in patients with chronic atrophic autoimmune gastritis. World J Gastrointest Oncol 2023; 15(8): 1451-1460
- URL: https://www.wjgnet.com/1948-5204/full/v15/i8/1451.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i8.1451